Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection

被引:9
作者
Goldwirt, Lauriane [1 ]
Barrail-Tran, Aurelie [1 ]
Da Cruz, Maria [1 ]
Taburet, Anne-Marie [1 ]
Furlan, Valerie [1 ]
机构
[1] CHU Bicetre, AP HP, Toxicol Lab, Pharm Clin, F-94270 Le Kremlin Bicetre, France
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2010年 / 878卷 / 3-4期
关键词
Raltegravir; High-performance liquid chromatography; Photodiode array detection; INTEGRASE INHIBITOR RALTEGRAVIR; HEALTHY-SUBJECTS; MS METHOD; MK-0518; ETRAVIRINE; EXTRACTION; ATAZANAVIR;
D O I
10.1016/j.jchromb.2009.10.029
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A precise and accurate high-performance liquid chromatography (HPLC) method with photodiode array detection has been developed and validated for raltegravir, a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI). Plasma (300 mu L) was extracted with dichloromethane/hexane 50:50 (v/v) after addition of the internal standard, 6,7-dimethyl-2,3-di(2-pyridyl) quinoxaline. The compounds were separated using a dC18 column and detected with ultraviolet detection at 320 nm. The limit of quantification was 10 ng/mL for raltegravir. The method was linear and validated over a concentration range of 0-10,000 ng/mL. The intra-day precision ranged from 3.1 to 12.3%, while the intra-day accuracy ranged from -15.0 to -0.5%, the inter-day precision and accuracy were less than 7%. The mean recovery was 76.8%. Application to clinical samples taken from patients treated with raltegravir indicated that the method is suitable for measuring plasma concentrations of raltegravir in pharmacokinetic studies of clinical trials. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:456 / 460
页数:5
相关论文
共 19 条
[1]   Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects [J].
Anderson, Matt S. ;
Kakuda, Thomas N. ;
Hanley, William ;
Miller, Jutta ;
Kost, James T. ;
Stoltz, Randall ;
Wenning, Larissa A. ;
Stone, Julie A. ;
Hoetelmans, Richard M. W. ;
Wagner, John A. ;
Iwamoto, Marian .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (12) :4228-4232
[2]  
COOPER D, 2007, CROI, V14
[3]   An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients [J].
D'Avolio, Antonio ;
Baietto, Lorena ;
Siccardi, Marco ;
Sciandra, Mauro ;
Simiele, Marco ;
Oddone, Valentina ;
Bonora, Stefano ;
Di Perri, Giovanni .
THERAPEUTIC DRUG MONITORING, 2008, 30 (06) :662-669
[4]   A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine [J].
Fayet, A. ;
Beguin, A. ;
Zanolari, B. ;
Cruchon, S. ;
Guignard, N. ;
Telenti, A. ;
Cavassini, M. ;
Guenthard, H. F. ;
Buclin, T. ;
Biollaz, J. ;
Rochat, B. ;
Decosterd, L. A. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (11-12) :1057-1069
[5]   Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects [J].
Iwamoto, M. ;
Wenning, L. A. ;
Petry, A. S. ;
Laethem, M. ;
De Smet, M. ;
Kost, J. T. ;
Merschman, S. A. ;
Strohmaier, K. M. ;
Ramael, S. ;
Lasseter, K. C. ;
Stone, J. A. ;
Gottesdiener, K. M. ;
Wagner, J. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :293-299
[6]   Atazanavir modestly increases plasma levels of raltegravir in healthy subjects [J].
Iwamoto, Marian ;
Wenning, Larissa A. ;
Mistry, Goutam C. ;
Petry, Amelia S. ;
Liou, Sarah Y. ;
Ghosh, Kaylan ;
Breidinger, Sheila ;
Azrolan, Neal ;
Gutierrez, Maria J. ;
Bridson, William E. ;
Stone, Julie A. ;
Gottesdiener, Keith M. ;
Wagner, John A. .
CLINICAL INFECTIOUS DISEASES, 2008, 47 (01) :137-140
[7]   Metabolism and disposition in humans of raltegravir (MK-0518), an Anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme [J].
Kassahun, Kelem ;
McIntosh, Ian ;
Cui, Donghui ;
Hreniuk, David ;
Merschman, Shelia ;
Lasseter, Kenneth ;
Azrolan, Neal ;
Iwamoto, Marian ;
Wagner, John A. ;
Wenning, Larissa A. .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) :1657-1663
[8]   A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma [J].
Long, Mary C. ;
Bennetto-Hood, Chantelle ;
Acosta, Edward P. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 867 (02) :165-171
[9]   Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS [J].
Merschman, S. A. ;
Vallano, P. T. ;
Wenning, L. A. ;
Matuszewski, B. K. ;
Woolf, E. J. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 857 (01) :15-24
[10]   Simultaneous Determination of Maraviroc and Raltegravir in Human Plasma by HPLC-UV [J].
Notari, Stefania ;
Tommasi, Chiara ;
Nicastri, Emanuele ;
Bellagamba, Rita ;
Tempestilli, Massimo ;
Pucillo, Leopoldo Paolo ;
Narciso, Pasquale ;
Ascenzi, Paolo .
IUBMB LIFE, 2009, 61 (04) :470-475